Middle East Journal of Cancer

metrics 2024

Exploring innovative solutions in cancer studies.

Introduction

Middle East Journal of Cancer, with an ISSN of 2008-6709 and an E-ISSN of 2008-6687, is a prominent open-access journal published by Shiraz University of Medical Sciences since 2010. Based in Iran, the journal aims to advance the knowledge and understanding of cancer research and oncology through the dissemination of high-quality, peer-reviewed articles. With open access availability, it promotes global collaboration and accessibility in research, making findings readily available to a wider audience. The journal is categorized in Q4 for both Cancer Research and Oncology as of 2023, highlighting its emerging presence in these fields. Alongside its Scopus ranks, where it positions 319th out of 404 in Medicine - Oncology and 198th out of 230 in Biochemistry, Genetics and Molecular Biology - Cancer Research, it serves as a platform for researchers, professionals, and students to enrich their expertise and contribute to the evolving landscape of cancer studies. The journal's continuous commitment to quality and accessibility represents an essential resource for those dedicated to advancing cancer research and improving patient outcomes in the Middle East and beyond.

Metrics 2024

SCIMAGO Journal Rank0.23
Journal Impact Factor0.40
Journal Impact Factor (5 years)0.50
H-Index11
Journal IF Without Self0.40
Eigen Factor0.00
Normal Eigen Factor0.07
Influence0.12
Immediacy Index0.10
Cited Half Life4.20
Citing Half Life8.90
JCI0.09
Total Documents518
WOS Total Citations201
SCIMAGO Total Citations505
SCIMAGO SELF Citations26
Scopus Journal Rank0.23
Cites / Document (2 Years)0.45
Cites / Document (3 Years)0.45
Cites / Document (4 Years)0.47

Metrics History

Rank 2024

Scopus

Oncology in Medicine
Rank #319/404
Percentile 21.04
Quartile Q4
Cancer Research in Biochemistry, Genetics and Molecular Biology
Rank #198/230
Percentile 13.91
Quartile Q4

IF (Web Of Science)

ONCOLOGY
Rank 304/322
Percentile 5.70
Quartile Q4

JCI (Web Of Science)

ONCOLOGY
Rank 307/322
Percentile 4.66
Quartile Q4

Quartile History

Similar Journals

Journal of Cancer Prevention

Transforming Knowledge into Action Against Cancer.
Publisher: KOREAN SOC CANCER PREVENTIONISSN: 2288-3649Frequency: 4 issues/year

Journal of Cancer Prevention is a pivotal scholarly publication dedicated to advancing research and knowledge in the field of cancer prevention and control. Published by the Korean Society for Cancer Prevention, this journal serves as a platform for innovative studies that focus on strategies to mitigate cancer risk factors, enhance early detection, and improve public health policies. With an ISSN of 2288-3649 and E-ISSN of 2288-3657, the journal ensures wide accessibility to emerging evidential research, contributing significantly to the global discourse on cancer prevention. Though currently not an open-access journal, Journal of Cancer Prevention remains committed to disseminating high-quality research, emphasizing rigorous peer review processes and upholding scientific integrity. Researchers, healthcare professionals, and students alike are encouraged to engage with the journal’s contributions that aim to forge collaborative pathways towards effective cancer prevention strategies in diverse populations.

Southern African Journal of Gynaecological Oncology

Exploring regional challenges in gynecological cancer treatment.
Publisher: MEDPHARM PUBLICATIONS PTY LTDISSN: 2074-2835Frequency: 2 issues/year

The Southern African Journal of Gynaecological Oncology, published by MEDPHARM PUBLICATIONS PTY LTD, is a leading open-access journal that has been at the forefront of disseminating critical research in the field of gynecological oncology since its inception in 2009. With an ISSN of 2074-2835 and an E-ISSN of 2220-105X, this journal serves as a vital resource for researchers, healthcare professionals, and students interested in the nuanced complexities of women's health, particularly in the context of Southern Africa. The journal is dedicated to promoting innovative findings and clinical practices to enhance patient care in gynecological cancer treatment and prevention. Its open-access model ensures that high-quality, peer-reviewed research is readily available to a global audience, fostering collaboration and knowledge sharing within the academic community. As the journal continues to grow, it emphasizes the importance of addressing regional health challenges and advancing the discourse in gynecological oncology.

Journal of Cancer

Connecting researchers to transform cancer care.
Publisher: IVYSPRING INT PUBLISSN: 1837-9664Frequency: 12 issues/year

Journal of Cancer is a premier, peer-reviewed academic journal published by IVYSPRING INTERNATIONAL PUBLISHING that focuses on advancing the field of oncology. With an impact factor reflecting its significant contributions, this journal ranks in the 80th percentile of medical journals pertaining to oncology, positioning it at #79 out of 404 in Scopus. Since its inception in 2010, the journal has embraced an Open Access model, ensuring that groundbreaking research reaches a global audience without barriers. Based in Australia, the journal addresses a wide array of topics within cancer research, catering to researchers, healthcare professionals, and students committed to enhancing their understanding of the complexities of cancer. Amidst evolving challenges in oncology, the Journal of Cancer serves as a vital platform for disseminating innovative findings, fostering collaboration, and promoting informed decisions that can lead to improved cancer outcomes worldwide.

BULLETIN DU CANCER

Exploring the frontiers of oncology research.
Publisher: ELSEVIER MASSON, CORP OFFISSN: 0007-4551Frequency: 12 issues/year

BULLETIN DU CANCER is a pivotal academic journal dedicated to the field of oncology, providing a platform for innovative research and insights into cancer treatment and diagnostics. Published by Elsevier Masson, Corp Off in France, this journal has been a part of the scientific community since 1966, and is committed to sharing critical findings that influence clinical practices and improve patient outcomes. Despite its recent rankings placing it in the Q4 category for Cancer Research and Q3 for Hematology and other related fields, BULLETIN DU CANCER remains essential for those interested in the latest developments in cancer biology and treatment methodologies. With an emphasis on both basic and clinical research, it serves as a valuable resource for researchers, healthcare professionals, and students seeking to deepen their understanding in various dimensions of oncology. This journal is particularly relevant as it continues to spotlight emerging research trends and supports the global imperative to combat cancer more effectively.

INDIAN JOURNAL OF CANCER

Bridging Research and Practice in Cancer Care
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0019-509XFrequency: 4 issues/year

INDIAN JOURNAL OF CANCER, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of oncology, providing dedicated insight into cancer research and its clinical applications since its inception in 1965. With an ISSN of 0019-509X and an E-ISSN of 1998-4774, this esteemed journal facilitates the dissemination of knowledge related to cancer prevention, diagnosis, and treatment strategies within the Indian context and beyond. Although classified within the Q3 quartile of oncology journals and ranked #292 out of 404 in its category in the Scopus database, the INDIAN JOURNAL OF CANCER continues to play a vital role in advancing the dialogue around cancer management. This journal is particularly significant for researchers, professionals, and students intent on contributing to the evolving landscape of oncology, offering a platform for sharing innovative findings and fostering collaboration among the academic community. Located in Mumbai, India, the journal's commitment to impactful research is reflected in its ongoing efforts to bridge gaps in cancer knowledge and address the unique challenges faced within the region and globally.

Journal of Gastrointestinal Cancer

Fostering discovery for better patient outcomes.
Publisher: SPRINGERISSN: 1941-6628Frequency: 4 issues/year

Journal of Gastrointestinal Cancer, published by SPRINGER, stands as a crucial resource in the fields of Gastroenterology and Oncology. With an ISSN of 1941-6628 and E-ISSN of 1941-6636, this journal has been committed to advancing the understanding and treatment of gastrointestinal cancers since its inception in 2007 and is poised to continue until 2024. The journal is recognized in the Q3 quartiles for both Gastroenterology and Oncology as of 2023, reflecting its relevance and contribution to these vital areas of medical research. Despite not being an open-access journal, it offers printed and online subscription options for access, ensuring that valuable research reaches the hands of practitioners, researchers, and students alike. With a focus on disseminating original research, reviews, and case studies, the Journal of Gastrointestinal Cancer plays a pivotal role in fostering ongoing education and discovery in the fight against cancer, promoting better patient outcomes worldwide. The journal is also indexed in Scopus, with notable rankings in the 50th and 45th percentiles for Gastroenterology and Oncology, respectively, further underscoring its scientific merit and credibility in the academic community.

Infectious Agents and Cancer

Advancing the frontier of cancer research through infectious insights.
Publisher: BMCISSN: 1750-9378Frequency: 1 issue/year

Infectious Agents and Cancer is a pivotal open access journal published by BMC, dedicated to advancing research at the intersection of infectious diseases and oncology. Since its inception in 2006, this journal has provided a platform for the exploration of the complex relationships between infectious agents and cancer development, aimed at researchers, healthcare professionals, and students alike. With a broad scope encompassing epidemiology and cancer research, the journal holds an impressive ranking in the Q3 quadrant for epidemiology, infectious diseases, and oncology in 2023, while also featuring in the Q4 category for cancer research. This distinguished journal not only contributes to the enrichment of scientific knowledge but also fosters collaborative efforts towards innovative solutions in the fight against cancer. Being part of the UK publishing landscape, the journal is accessible to a global audience, ensuring that vital research findings are disseminated widely to inform policy and practice in health sciences.

Molecular and Clinical Oncology

Uncovering the molecular secrets of oncology.
Publisher: SPANDIDOS PUBL LTDISSN: 2049-9450Frequency: 12 issues/year

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

International Journal of Cancer Management

Advancing cancer care through innovative research.
Publisher: BRIEFLANDISSN: 2538-4422Frequency: 12 issues/year

The International Journal of Cancer Management is a distinguished publication dedicated to advancing knowledge and research in the fields of cancer management, oncology, pharmacology, and radiology. Published by BRIEFLAND in the Netherlands, this journal serves as a vital resource for researchers, healthcare professionals, and students interested in the latest developments in cancer care and treatment strategies. With an ISSN of 2538-4422 and an E-ISSN of 2538-497X, the journal features a range of peer-reviewed articles that cover diverse aspects of cancer management, reflecting its commitment to high-quality, impactful research. The journal ranks in the Q4 category for Cancer Research and Oncology and Q3 for both Pharmacology and Surgery in 2023, signifying its growing influence in the scientific community. Through its open access format, the International Journal of Cancer Management ensures that critical research findings are accessible to all, promoting collaboration and innovation in the battle against cancer. Researchers looking to share their findings or learn more about current trends will find this journal an invaluable addition to their professional toolkit.

CANCER INVESTIGATION

Illuminating pathways in oncology through peer-reviewed excellence.
Publisher: TAYLOR & FRANCIS INCISSN: 0735-7907Frequency: 10 issues/year

CANCER INVESTIGATION is a distinguished peer-reviewed journal published by Taylor & Francis Inc, dedicated to the advancing field of cancer research and oncology. With an ISSN of 0735-7907 and E-ISSN of 1532-4192, this journal has been a pivotal resource for professionals and researchers since its inception in 1983, continually contributing to the evolving landscape of cancer investigation until its convergence in 2024. CANCER INVESTIGATION boasts noteworthy rankings in 2023, including Q3 in Cancer Research and Q2 in Medicine (miscellaneous), highlighting its relevance and impact in these critical areas. The journal's commitment to disseminating innovative research and comprehensive reviews makes it an essential platform for those engaged in cancer studies and related disciplines. While currently not available as an open-access publication, CANCER INVESTIGATION remains an invaluable tool for understanding the complexities of cancer, offering insights that drive scientific advancements and improve patient outcomes.